keyword
MENU ▼
Read by QxMD icon Read
search

GARFIELD-AF

keyword
https://www.readbyqxmd.com/read/27832408/erratum-to-the-global-anticoagulant-registry-in-the-field%C3%A2-atrial-fibrillation-garfield-af-exploring-the-changes-in-anticoagulant-practice-in-patients-with-non-valvular-atrial-fibrillation-in-the-netherlands
#1
https://www.readbyqxmd.com/read/27792741/quality-of-vitamin-k-antagonist-control-and-1-year-outcomes-in-patients-with-atrial-fibrillation-a-global-perspective-from-the-garfield-af-registry
#2
Sylvia Haas, Hugo Ten Cate, Gabriele Accetta, Pantep Angchaisuksiri, Jean-Pierre Bassand, A John Camm, Ramon Corbalan, Harald Darius, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Barry Jacobson, Gloria Kayani, Lorenzo G Mantovani, Frank Misselwitz, Karen Pieper, Sebastian M Schellong, Janina Stepinska, Alexander G G Turpie, Martin van Eickels, Ajay K Kakkar
AIMS: Vitamin K antagonists (VKAs) need to be individually dosed. International guidelines recommend a target range of international normalised ratio (INR) of 2.0-3.0 for stroke prevention in atrial fibrillation (AF). We analysed the time in this therapeutic range (TTR) of VKA-treated patients with newly diagnosed AF in the ongoing, global, observational registry GARFIELD-AF. Taking TTR as a measure of the quality of patient management, we analysed its relationship with 1-year outcomes, including stroke/systemic embolism (SE), major bleeding, and all-cause mortality...
2016: PloS One
https://www.readbyqxmd.com/read/27647168/evolving-antithrombotic-treatment-patterns-for-patients-with-newly-diagnosed-atrial-fibrillation
#3
A John Camm, Gabriele Accetta, Giuseppe Ambrosio, Dan Atar, Jean-Pierre Bassand, Eivind Berge, Frank Cools, David A Fitzmaurice, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Gloria Kayani, Yukihiro Koretsune, Lorenzo G Mantovani, Frank Misselwitz, Seil Oh, Alexander G G Turpie, Freek W A Verheugt, Ajay K Kakkar
OBJECTIVE: We studied evolving antithrombotic therapy patterns in patients with newly diagnosed non-valvular atrial fibrillation (AF) and ≥1 additional stroke risk factor between 2010 and 2015. METHODS: 39 670 patients were prospectively enrolled in four sequential cohorts in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): cohort C1 (2010-2011), n=5500; C2 (2011-2013), n=11 662; C3 (2013-2014), n=11 462; C4 (2014-2015), n=11 046...
September 19, 2016: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/27623681/rivaroxaban-real-world-evidence-validating-safety-and-effectiveness-in-clinical-practice
#4
Jan Beyer-Westendorf, A John Camm, Craig I Coleman, Sally Tamayo
Randomised controlled trials (RCTs) are considered the gold standard of clinical research as they use rigorous methodologies, detailed protocols, pre-specified statistical analyses and well-defined patient cohorts. However, RCTs do not take into account the complexity of real-world clinical decision-making. To tackle this, real-world data are being increasingly used to evaluate the long-term safety and effectiveness of a given therapy in routine clinical practice and in patients who may not be represented in RCTs, addressing key clinical questions that may remain...
September 28, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27561277/the-global-anticoagulant-registry-in-the-field-atrial-fibrillation%C3%A2-garfield-af-exploring-the-changes-in-anticoagulant-practice-in-patients-with-non-valvular-atrial-fibrillation-in-the-netherlands
#5
V Ten Cate, H Ten Cate, F W A Verheugt
There are over 385,000 cases of atrial fibrillation (AF) in the Netherlands, with over 45,000 new cases each year. Among other things, AF patients are at high risk of stroke. Patients are often prescribed oral anticoagulation, such as vitamin K antagonists (VKA), to mitigate these risks. A recently introduced class of oral anticoagulants, non-vitamin K antagonists (NOAC), is quickly gaining currency in global clinical practice. This study provides insight into the changes these new drugs will bring about in Dutch clinical practice...
October 2016: Netherlands Heart Journal
https://www.readbyqxmd.com/read/27552578/vitamin-k-antagonist-control-in-patients-with-atrial-fibrillation-in-asia-compared-with-other-regions-of-the-world-real-world-data-from-the-garfield-af-registry
#6
Seil Oh, Shinya Goto, Gabriele Accetta, Pantep Angchaisuksiri, A John Camm, Frank Cools, Sylvia Haas, Gloria Kayani, Yukihiro Koretsune, Toon Wei Lim, Frank Misselwitz, Martin van Eickels, Ajay K Kakkar
OBJECTIVE: To compare the distribution of international normalized ratios (INRs) in patients receiving vitamin K antagonist (VKA) for newly diagnosed atrial fibrillation in Eastern and Southeastern Asia and in other regions of the world (ORW) represented in the ongoing, global observational study GARFIELD-AF. METHODS AND RESULTS: 3621 and 13,541 patients were recruited prospectively in 2010-2013 from Asia and ORW, respectively. At baseline, excluding patients with unknown antithrombotic treatment, 1356 (37...
November 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27357359/two-year-outcomes-of-patients-with-newly-diagnosed-atrial-fibrillation-results-from-garfield-af
#7
Jean-Pierre Bassand, Gabriele Accetta, Alan John Camm, Frank Cools, David A Fitzmaurice, Keith A A Fox, Samuel Z Goldhaber, Shinya Goto, Sylvia Haas, Werner Hacke, Gloria Kayani, Lorenzo G Mantovani, Frank Misselwitz, Hugo Ten Cate, Alexander G G Turpie, Freek W A Verheugt, Ajay K Kakkar
AIMS: The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the first year. METHODS AND RESULTS: GARFIELD-AF is an ongoing, global observational study of adults with newly diagnosed NVAF. Two-year outcomes of 17 162 patients prospectively enrolled in GARFIELD-AF were analysed in light of baseline characteristics, risk profiles for stroke/systemic embolism (SE), and antithrombotic therapy...
June 29, 2016: European Heart Journal
https://www.readbyqxmd.com/read/27071942/comparison-of-international-normalized-ratio-audit-parameters-in-patients-enrolled-in-garfield-af-and-treated-with-vitamin-k-antagonists
#8
David A Fitzmaurice, Gabriele Accetta, Sylvia Haas, Gloria Kayani, Hector Lucas Luciardi, Frank Misselwitz, Karen Pieper, Hugo Ten Cate, Alexander G G Turpie, Ajay K Kakkar
Vitamin K antagonist (VKA) therapy for stroke prevention in atrial fibrillation (AF) requires monitoring of the international normalized ratio (INR). We evaluated the agreement between two INR audit parameters, frequency in range (FIR) and proportion of time in the therapeutic range (TTR), using data from a global population of patients with newly diagnosed non-valvular AF, the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF). Among 17 168 patients with 1-year follow-up data available at the time of the analysis, 8445 received VKA therapy (±antiplatelet therapy) at enrolment, and of these patients, 5066 with ≥3 INR readings and for whom both FIR and TTR could be calculated were included in the analysis...
August 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26365937/stroke-prevention-in-atrial-fibrillation-patients-in-poland-and-other-european-countries-insights-from-the-garfield-af-registry
#9
Janina Stępińska, Elżbieta Kremis, Anna Konopka, Beata Wożakowska-Kapłon, Piotr Ruszkowski, Piotr Kukla, Gloria Kayani
BACKGROUND: Atrial fibrillation (AF) is the most common clinically-significant arrhythmia in the adult population, and it is a strong independent risk factor for cerebrovascular accidents. Patients with non-valvular AF are five times more likely to suffer a stroke. Despite the clear recommendations for anticoagulant therapy, many clinicians are still reluctant to provide routine oral anticoagulation to patients with AF, despite the potential clinical benefits. AIM: To compare Polish and European populations of patients with AF and the every-day practice of stroke prevention in Poland and in the rest of Europe...
2016: Kardiologia Polska
https://www.readbyqxmd.com/read/26069039/-garfield-af-first-data-on-healthcare-of-patients-with-atrial-fibrillation-in-germany
#10
Sylvia Haas
No abstract text is available yet for this article.
June 2015: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/25714828/does-sex-affect-anticoagulant-use-for-stroke-prevention-in-nonvalvular-atrial-fibrillation-the-prospective-global-anticoagulant-registry-in-the-field-atrial-fibrillation
#11
MULTICENTER STUDY
Gregory Y H Lip, Sophie K Rushton-Smith, Samuel Z Goldhaber, David A Fitzmaurice, Lorenzo G Mantovani, Shinya Goto, Sylvia Haas, Jean-Pierre Bassand, Alan John Camm, Giuseppe Ambrosio, Petr Janský, Wael Al Mahmeed, Seil Oh, Martin van Eickels, Pekka Raatikainen, Jan Steffel, Ali Oto, Gloria Kayani, Gabriele Accetta, Ajay K Kakkar
BACKGROUND: Among patients with atrial fibrillation (AF), women are at higher risk of stroke than men. Using prospective cohort data from a large global population of patients with nonvalvular AF, we sought to identify any differences in the use of anticoagulants for stroke prevention in women and men. METHODS AND RESULTS: This was a prospective multicenter observational registry with 858 randomly selected sites in 30 countries. A total of 17 184 patients with newly diagnosed (≤6 weeks) nonvalvular AF and ≥1 additional investigator-defined stroke risk factor(s) were recruited (March 2010 to June 2013)...
March 2015: Circulation. Cardiovascular Quality and Outcomes
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"